Biosimilars Explained | Drug Discovery & DDS

Back to Technology, Institution & Company Guides

TECHNOLOGY EXPLAINER

Biosimilars
— Exact copies are impossible, so developers must show that the distributions overlap

After chemical (generic) with predecessorSame compoundHome Biosimilar is not. Originally, protein produced by cellsMixture of different s such as sugar chainThat’s why. And recently, the main role of equality isFrom Clinical Trials to Analysis

Composition: U.S. Laws (42 U.S.C. 262), FDA guidance and approval notices, publication materials, guidelines of the Ministry of Health, Labour and Welfare, PMDA materials, ICH guidelines, and review papers (Pharmaceu Medicine/Nature Biotechnology/Frontiers in Immunology) as primary information / final update September 2026

Hero image: abstract image with two powder piles that look almost the same — **Concept diagram (AI generation image).**It is expressed as an atmosphere of the idea that "the two things that are not the same, but not the same" is not.We do not show actual medicines, original medicines and products.

Composition of this article

What is a biosimilar?
Differences from generics – “highly similar” instead of “same”
How to Show Equality: "Total Evidence" from Analysis to Clinical
What to compare with analysis
Material Technician Perspective 1: The “Precedent” itself is a target
manufacturing plant difficulties in manufacturing: host cells, sugar chains, impurities, preparations
FDA, , PMDA
What is interchangeability?
From Clinical Trials to Analysis - Review of Comparative Efficacy Tests
Perspective 2: When the analysis method becomes the main role of the examination
Issues and things that have not yet been determined
Glossary/Reference Materials/Reference Table

Facts= Contents described in the publication material (with source link)
The calculation of this paper= The value calculated based on the specified premise
Undetermined / Future= Items that have not been confirmed as a plan and goal
In addition to this, it is possible to organize structures and read materials and process designs."Description"is distinguished.

Medical care

About this articleExplanation of the quality evaluation, manufacturing and regulation of biosimilars from the perspective of materials and analysisComment We do not evaluate the effectiveness and safety of certain products, and do not give superiority to predecessors, biosimilars, or biosimilars. It is not medical advice, it is not recommended to switch the drug.Please contact your doctor or pharmacist for any changes or selection of the eutic drugs.

1. What is a biosimilar?

What:The guidelines of the Ministry of Health, Labour and Welfare are biosimilars.“Pharmaceu、s developed by different manufacturers as pharmaceuticals with the same quality, safety and efficacy as biotechnology applied drugs (precedent biopharmaceu、s) that have already been approved as new active ingredients in Japan”definedFacts
US Definition:US law biosimilar"Notwithstanding the slightest difference in clinically inert ingredients, it is highly similar to reference products."Home"In terms of safety, purity and accuracy, there is no clinically meaningful difference between predecessors"Determined asFacts
Why don’t you say “I”?Why biosimilars are not considered biological formulation generics,“Natural variations and more complex manufacturing of biological formulations do not allow precise replication of the micro-uniformity of、s.”That’s whyFacts

The best line in this article

The development of biosimilars is not a job of creating the same distribution, but a job of creating the same overlap. In addition, the predecessor's predecessor's predecessor's product itself will be changed every timeDistribution that works little by littleComment ICH Q5E indicates the equivalent before and after process change"It does not necessarily mean that quality characteristics are identical, and is highly similar."FactsHome Biosimilar,another company in another processIt is a challenge to realize (explanation by this article).

2. Differences from generics – “highly similar” instead of “same”

The guidelines of the Ministry of Health, Labour and Welfare are described as follows: Since bio process is used for manufacturing, it is essential to produce uneven structures.Home For that reasonIt is difficult to demonstrate the identity of active ingredients of pre-biopharmaceuticals and bio-coined products.Home A similar approach to chemical drugs with the same structure as those of predecessor drugs cannot be applied.Facts。

ICH Q6B“Since bio、 process is used for the production of organisms, biological structural unevenness occurs in proteins.”HOME Objectives"It can be a mixture of predicted post-translation modifiers (e.g. sugar chain modifiers)"FactsHome For example, IgG antibodyN-bonded sugar chain with 297 positions attached to each heavy chainThere are differences in the sugar chain, such as dandruff, galactose and sialic acid.Facts。

Fig. 1 Concept diagram (vector drawing).The fact that biopharmaceu s are essentially uneven and difficult to demonstrate the identity is based on the guidelines of the Ministry of Health, Labour and Welfare [Reference Material 11] and the compound of the post-translation modifier can be based on ICH Q6B [Reference Material 19].Lines and curves are imitations that show the idea, and do not indicate actual measurement data or distribution of specific products.

3. How to show validity: The Total Evidence from Analysis to Clinical

The U.S. law requires the following data to apply for a biosimilarFacts。

Analysis test:Notwithstanding the slightest difference in clinically inert ingredients, it indicates that it is highly similar to predecessors
Toxicity Rating:Depending on the analytical and clinical trials, or may be composed of them ( Changed from animal testing until 2022
Clinical Trials:Ensuring the evaluation of immunogenicity and pharmacokinetics or pharmacokinetics is sufficient to indicate safety, purity and potency in one or more appropriate terms of use

Pre-orderThe same mechanismuse (to the extent that the mechanism of action is known) is also a requirementFactsHome FDA’s dance proposal in October 2025 is sufficient for analysis, drug delivery and immunogenic data."Totality of the evidence submitted in the application for biologics approval"rated as wellFacts。

Fig. 2 Concept diagram (vector drawing).The type of data required for the application is based on the FDA’s dance draft in October 2025, and ICH M18 concept paper.The shape of the pyramid and the width of each layer are imitation by this article, and it does not indicate the size or cost ratio of each test.

4. What to compare with analysis

The guidelines of the Ministry of Health, Labour and Welfare show the contents of the quality comparison test:Facts。

Compare	Description of Guidelines (Summary/Quotation)
Structure/Physical Properties	Amino acid sequence, diphosphate bond, sugar chain structure, and other post-translational modifiers, subunit structures, etc."If there is a difference in the primary structure, it is not considered a bioco、ity."Home If there is a difference in unevenness caused by post-translational modifications such as N-ter。 and C-ter。 processing, it is guaranteed that it does not affect clinical efficacy and safety. Comparing secondary and secondary structures
Biological Properties	Compare biological activity in multiple ways possible. In addition to the binding activity with antigens, it is necessary to compare the binding activity with neutralization, Fcγ receptor, fetal Fc receptor, supplement C1q, ADCC activity, CDC activity, etc.
Impurities	Comparing the type and quantity of impurities。 from the target substance (such as cutting and coagulation).because it is suggested that the association of immunity and can be of various sizes and shapes,Multiple analysis methods with different principlesTry to compare
Impurities produced from the manufacturing process	It is not necessary to compare because it is different depending on the process. However, compared to the same analysis method that the protein composed is different in both people, such as the EL、-derived protein testThere is a possibility that the difference in the actual residual amount due to the specificity of the analysis methodHome
Quality characteristics related to immunity	Structure of post-translational modifiers, impurities derived from the object, and impurities derived from the manufacturing process can produce different immune responses. Because it is difficult to evaluate in non-clinical trials, it is also useful for clinical trial planning to identify differences in quality comparisons

AllFacts(Ministry of Health, Labour and Welfare "Guideline for Ensuring the Quality, Safety and Validity of Bio-co。ed Products" February 4, 2020 [Reference Material 11]) The same guideline is for comparison“What is produced by manufacturing methods for commercial products”In principle,Multi lotthe degree of similarity in comparison with the original or formulation ofFacts。

How many types of biosimilars can be made with only sugar chain combinations

IgG’s two heavy chains come with one 297 N-bonded sugar chainFacts。 Premise:The type of sugar chain attached to each part is5 typesAssuming that it is possible, two heavy chains are not distinguished (replacement of left and right is regarded as the same molecule). Assumption of this articleThe calculation of this paper。

5 different types: 5 × 4 ÷ 2 = 10 → Total 15 streets
Type10 types10 + 45 = 55 streets

Premises and Limits:The number of types is assumptions for explanation, and does not indicate the actual type of sugar chain or the presence ratio. The combination is further improved by multiplying the differences in other modifiers such as the end of the C."One antibody product" is actually a mixture of many speciesIt is a calculation to show it in a digit.

5. Material ians’ Perspective 1: The “Precedent” itself is a target

Reading of Material Engineers: The center of the standard is determined by "Buying and measuring opponent's lot"

The development of biosimilars is easy to overlook.The other party (precedent) is not constantComment ICH Q5EWhen the same manufacturer (including contract manufacturers) changes its manufacturing methodThis is a guideline that defines how to directly compare the products before and after the change.FactsHome In other wordsThe manufacturer of predecessor products continues to reflect their products by changing the manufacturing process and showing "highly similarity" each time.It is.

Sch、l et al from the market 20112007 - 2010Get itAranesp, R xan/Mabthera, EnbrelAnalyze quality profiles and Compare the b before and after the process change,Example of "admissible quality characteristic variation" in products that continue to sell without changing the displayShownFacts。

The guidelines of the Ministry of Health, Labour and Welfare are based on this situation.Identification of crucial quality characteristics (CQA) and the tolerance setting "The lot analysis results of pre-biopharmaceuticals become important information"HOME To change our manufacturing processEvaluation according to ICH Q5EContact UsFacts。

In the words of material engineers, this is"We collect a large number of commercial lots of competitors and decide the window of our standard from the width of the distribution"It is work (explanation by this article). If the distribution of the opponent depends on the time,When to make a lotThe window will change. Biosimilar Quality DesignDesign to chase movement distribution rather than fixed target valuesRead this article.

Figure 3 Concept diagram (vector drawing).Sch l et al (2011) [Reference Material 16], ICH Q5E [Reference Material 14], ICH Q5E [Reference Material 14], ICH Q5E [Reference Material 14], ICH Q5E [Reference Material 14], the policy of Ministry of Health, Labour and Welfare [Reference Material 11] that the results of the preliminary lot analysis are important for the tolerance setting.The point, band, and change orientation are all imitation, and it does not indicate the actual measurement of specific products and quality characteristics.

6. difficulty in manufacturing ― injured cell, sugar chain, impurities, preparation

Biosimilar suppliers can not use cell stock or process conditions of predecessor manufacturers. Ministry of Health, Labour and Welfare"We develop our own manufacturing method, perform quality characteristic analysis, formulation design, etc."It is necessary to build a management strategy that can always be manufactured throughout the product lifecycleFacts。

	Guideline Description	Meanings from Materials and Processes
Home	Host cellPost-translation modifiers such as sugar chains and profiles of injured cellsContact Us If the predecessor cell is clearThe same host cell is preferredHowever, if you use different cells, it is better to consider the impurity profile.	cells are affected by "catalyst in the reactor". If the catal changes, the face of the sub-product changes
Sugar chain	Even if the host cell is the same,In ation sites and culture conditions of gene expression componentsVarious factors such asHighly uniformity of sugar chainKnown	In the same cell and the same array, distribution is performed in medium and culture conditions. Process conditions determine the composition distribution close to the composition distribution of copolymers
	Dosage route is the same as predecessorshould be. If the form is reasonable, it is useful (e.g. liquid agent for freeze-drying),The same formulation is not requiredHome Prescription using highly safe additives	Additives, containers, and chemical forms remain the freedom of design in the equivalent frame. It can be an entrance to the material supplier
Comparison contrast	As a rule, control drugsDomestic Approved ProductsHome In the case of using overseas approved products, we will explain that it is 、 to be the same as domestic approved products in the quality comparison test etc.	In the same product name, it is necessary to analyze the "identity" of the lot per region.

All "Guideline description"Facts(Reference Material 11) This article explains the right column.

7. Regulations: FDA, FDA, PMDA

	USA (FDA)	European( )	Japan (Ministry of Health, Labour and Welfare)
Contact Us	biosimilar: There is no clinical difference in safety, purity and potency similar to predecessors.	biosimilar: highly similar in terms of approved biological formulation and structure, bioactive, efficacy, safety, and immunogenic profiles	Bio-co ed products: equivalent to predecessive biopharmaceu s / with the same quality, safety and effectiveness
First Approval	Zarxio（filgrastim-sndz）March 6, 2015(351(k) route BLA	2006	Somatropin BS "Sand"June 2009PMDA
Number of approvals	As of March 202682 Biosimilarshave been approved	2006 - 202286 itemsapproved (including those sold in the EU)	Antibody Biosimilar18 items by December 2023(PM by PMDA staff)
Time to apply	Priority first approval4 yearsYou can apply afterward, and you can get approval.12 yearsClose	Generally, from prior approvalat least 8 yearsApply Now	Precedent Biopharmaceu sExpiration periodApplicability with etc.
Name	Core Name+A suffix with four lowercase characters that don’t make sense(e.g. filgrastim-sndz)	— (not confirmed in this article)	Sales name with "BS" and "Sand" in general name (e.g. Somatropin BS "Sand")
Compatibility	Legal「interchangeable」Chapter 8	Biosimilars and HMA approved biosimilars in the EUScientific compatibilityPublish a statement	The guideline referenced by this article does not describe the United States-like compatibility specification system

AllFacts(U.S. Law [Reference Materials 1], FDA [Reference Materials 3, 5, 6, 8, FDA [Reference Materials 9, 10], Ministry of Health, Labour and Welfare Guidelines [Reference Materials 11], PMDA training materials [Reference Materials 12], Goto et al. [Reference Materials 13]). The name of this document is "-" because it is not checked in this article.

Figure 4 Drawing including calculation of this paper (vector drawing).US law (42 U.S.C. 262(k)(7))), European 8 years refer to FDA's description [Reference Material9], Zarxio's predecessor Neupogen's 12's approval and 24 years' FDA's fact sheet [Reference Material 8].The length of the rod is converted by this article, and detailed conditions such as extension of the protection period are omitted.This article explains how to read the term “system” to start the system.

8. What is interchangeability?

(1) U.S.: “」atible” under law

U.S. law “interchangeable”"Replace with predecessor products without intervention of medical workers who predetermined predecessor"FactsHome In addition to its requirements being biosimilar,"I can expect to produce the same clinical results as predecessors in all patients."Comment In products that are administered multiple times"The risk of safety risks and efficacy is not greater than the risk when using predecessors without switching"CommentFacts。

First Compatibility Judgment:FDA approval noticeSemglee（insulin glargine-yfgn）3 mL pen with 10 mL vial,"The first biological formulation that has been judged to be compatible with any terms of use"Signing DateJuly 28, 2021HomeFacts
Insulin framework changes:InsulinMarch 23, 2020We have confirmed the product group that the approval up to it is to the approval of the biological formulationFactsHome Semglee351(k)Being accepted on July 29, 2020FactsSystem migration opens the process of biosimilar compatibility in insulinRead this article
Bionsimilar review:[On June 20, 2024, the FDA announced the revision of the dance on compatibility,]Switching tests are generally not necessaryI thought. approved at the time9 Compatibility Biosimilarshas been approved without additional clinical testing dataFacts

(2) Europe: scientifically compatible with approved

and the Director of Regulatory Authority (HMA) are joint statements,“The biosimilars approved by the EU are compatible.”HOME It is assumed that the biosimilar is used instead of the predecessor (or vice versa), which is replaced by another biosimilar of the same predecessor. HomeMethods such as automatic replacement (alternative preparation) at pharmacies are not authorized by the pharmacy.Facts。

Calculation of this paper: proportions approved without clinical testing

9 ÷ 13 = about 69%HomeThe calculation of this paper。 Premises and Limits:As of June 2024, subsequent approval is not included. It does not mean that the quality and safety of biosimilars that are not specified in compatibility are inferior. The FDA also has the same explanation, which makes it reliable for biosimilar safety and efficacy with or without compatibility approvalFacts。

9. From Clinical Trials to Analysis – Review of Comparative Efficacy Tests

The biggest change in the past few yearsComparative efficacy test (CES)Positioning CES is a large-scale clinical trial that compares the effectiveness of predecessors and biosimilars for patients.

FDA dance (October 2025)

"The comparison analysis evaluation (CAA) is generally more sensitive than CES and can detect if there is a difference between two products that could interfere with biosimilarity demonstration."Facts

and in the following cases:Simplified methods should be consideredFacts。

Precedents and biosimilar candidatesProduced from cloned cell strains, highly refined and fully analyzed by analysisHome
PrecedentsUnderstand the relationship between quality and clinical efficacyYou can evaluate the characteristics of the analysis method included in the CAA.
Similarity testing of drugs in humans is available and clinically meaningfulHome

FDA announced on March 9, 2026."Revoke unwanted comparability testing that can cost $24 million over 1-3 years"Explanation andSimplify clinical drug testingNew dance ProposalFacts。

This flow is international. ICHM18 “A framework to determine the usefulness of comparative efficacy testing in the biosimilar development program”concept paperNovember 19, 2025has been approved. CES"The sensitivity required to identify products that differ from quality characteristics"andModern analytical technology has the sensitivity to identify the difference between biosimilar and predecessorBackgroundFactsHome We aim to reduce the amount of clinical data required for the development and approval of biosimilars.Reflection paper on tailored clinical approachWe have adoptedFacts。

There is a paper that analyzes the results of Japan. PMDA Goto et al 2025,18 antibody biosimilars approved in Japan from 2014 to 2023review report, All 18 items were CESDifferences in quality characteristics64% are described in other quality characteristics data and only 6% of the results of the CESReported what wasFacts。

Figure 5 Drawing including calculation of this paper (vector drawing).The analysis of 18 antibody biosimilars in Japan is based on Goto et al (2025) [Reference Material 13], and 9 of 13 compatible biosimilars in the United States are based on the FDA's explanation [Reference Material 4].About 30% and about 69% are calculated by this article.It is not directly compared with two numbers that differ from the target and the time.

10. Perspective of Material Technician 2: When the analysis method becomes the main role of the examination

Abstract concept image of light passing through two closely matched transparent sheets to reveal subtle differences — **Figure 6 Concept diagram (AI generation image).**It is expressed as an atmosphere of comparative analysis that "T。 things are stacked together and the slight difference is distinguished by light".It does not indicate actual analyzer and measurement result.

The sensitivity of analysis is a replacement for clinical trials.

FDA dance"CAA is generally more sensitive than CES."FactsIt is important to see from the side of material and analysis. Analyze the role of the patient’s testing for yearsBecause the system is moving in the direction (explanation by this article).

The analysis method determines the development period as it is:If CES is omitted,Is it possible to fully analyze characteristics by improving quality characteristics?Contact UsFactsHome Separation, Mass Analysis, Spectroscopic, Photovoltaic, Cell Assay, etc.Resolution and repeatabilityHowever, it is directly linked to the development of the product.
Multiple methods with different principles are required:The guidelines of the Ministry of Health, Labour and Welfare have complex properties like aggregatesMultifaceted evaluation of multiple analytical methods with different principlesRecommended toFactsHome Particle size distribution is not only DLS, but also other principles.Orthogonal LawCommentary by this article
The "specificity" of the analytical reagent itself becomes a problem:EL of the host cell-derived protein is precedented and biosimilarIf the host cell is different, it is possible that the same reagent cannot be recognized fairlyHomeFacts。Measuring tools (antibody reagents) depend on the material being measuredIt is an interesting problem as an analysis chemical (in Japanese) Commentary by this article

You can't miss the freeness of the preparation. GuidelineDosage routes are identicalwhile askingThe same formulation is not required, but it is possible to change the form of the agent (such as freeze-drying and liquid agent) or to use a safer additive.Facts。 The active ingredient is "like predecessor", the preparation is "better"——This asymmetry is left behind the side of the container, additive, and device (in this article).

11. Challenges and things that have not yet been determined

(1) Treatment of Comparative Efficacy Tests is still at the stage of "Draft"

FDA dance in October 2025draftHomeFactsICH M18Concept Paper StageHomeFactsHome The final content and application time in each country are not confirmed at the time of the investigation (September 2026).Undetermined / Future。

(2) U.S. Compatibility dance is also revised

Revised in June 2024, which is generally unnecessary for testingPublished asFactsFDA's guidance proposal in October 2025(June 2024)See asFactsHome I couldn't confirm when the final version came out.Undetermined / Future。

(3) Not confirmed in Japan

The official ag ation of the regulatory authorities indicating the total number of biosimilars approved in Japan (all areas) was not confirmed within the scope of the survey. Chapter 7 "June 2009" is based on the list of PMDA training materials. Note that this document is based on the personal opinion of the presenter.
The primary information indicating the implementation of the U.S. compatibility specification system was not confirmed in the scope of the survey.Undetermined / Future
The number of policy targets and drug prices and penetration rates for promoting use is not handled outside the technical commentary of this article.

This article

Biosimilars are not identical but highly similar.It is difficult to demonstrate the sameness because of unevenness from bio .Facts
If there is a difference in the primary structure (amino acid sequence), it is not considered a biosimilarFacts
The predecessor works by changing the manufacturing process.Compared with "moving distribution"Facts
There are five types of sugar chains, and the combination of two heavy chains is 15The calculation of this paper
U.S. stipulates "compatible" by law, and Europe is scientifically compatible with approved biosimilarsFacts
The main role of equivalence is shifting from clinical trial to analysis.In 18 antibodies in Japan, differences described in CES were 6%Facts

12. Glossary

Biosimilar (Bio-biologics): Biopharmaceu s developed by another company to have the same quality, safety and efficacy.

Reference product: Ready-made biopharmaceu s for comparison of biosimilars.

valent / homogeneity: It is possible to judge scientifically if the similarity of quality characteristics is high, and even if there is a difference, it does not affect clinical efficacy and safety.

Unevenness: Molecules with different modifications such as sugar chain are mixed in the same product. essential to biopharmaceuticals.

After translation: Protein is synthesized in cells and then undergoes glycosylation (sugar chain addition).

Home: cells that produce recombinant proteins. CHO cells, etc.

HCP: Protein of impurities。 from cells used above. EL

: A mass of protein impurities suggested by the association of immunity.

Immunogenicity: The body's immune system reacts to the drug and makes antibodies.

Comparison Analysis Evaluation (CAA): Evaluation of the quality characteristics of predecessor and biosimilar by analysis.

Comparative efficacy test (CES): Clinical trials that compare the effectiveness of predecessors and biosimilars for patients.

Exchangeability: In the United States, it should be replaced with a predetermined product without the intervention of a prescription.

Switching test: A clinical trial that examines the effects of alternating predecessor and biosimilar.

ICH Q5E: International guidelines for evaluating the comparability of biopharmaceu s before and after process changes.

Orthogonal Law: Checking the same characteristics with multiple analytical methods of different principles.

: Grant the efficacy and effects that are not performed in clinical trials as well as explanations of the mechanism of action.

13. Reference materials (primary information)

Legal Information Institute「42 U.S. Code § 262 — Regulation of biological products」 — law.cornell.edu
FDA“Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated s for Assessing the Need for Comparative Efficacy Studies” October 2025 — fda.gov
FDAFDA Takes Further Steps to Streamline Biosimilar Development and Make Medicines More Affordable fda.gov
FDAFDA updates guidance on interchangeability fda.gov
FDA“Nonproprietary Naming of Biological Products:ancedance for Industry” January 2017 — fda.gov
FDA"BLA 125553 Approval Notice (Zarxio, filgrastim-sndz)" March 6, 2015 (PDF) — accessdata.fda.gov
FDA"BLA 761201 Approval Notice (Semglee, insulin rgine-yfgn)" July 28, 2021 (PDF) — accessdata.fda.gov
FDA「FACT SHEET: Bringing Lower-Cost Biosimilar Drugs to American Patients」（PDF） — fda.gov
European Medicines Agency「Biosimilar medicines: Overview」 — ema.europa.eu
EMA／HMA「Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU」EMA/627319/2022（PDF） — ema.europa.eu
Department of Health, Labour and Welfare"Guideline for Ensuring Quality, Safety and Efficacy of Bio-co)ed Products" (Pharmaceu) Drug Trial No. 0204, February 4, 2020) — mhlw.go.jp
Pharmaceutical Medical Devices (PMDA)"How to Improve the Quality of Biosimilars (Equality Assessment)" Recept Science Expert Workshop Material, January 28, 2026 (PDF) Note that the presenter’s personal opinions are based on (with) — pmda.go.jp
Goto, K., Hariu, A., Kuribayashi, R.「Survey on the Role of Comparative Efficacy Studies Required for Biosimilar Monoclonal Antibody Approval in Japan…」Pharmaceutical Medicine 39(6), 477–491 (2025). doi:10.1007/s40290-025-00583-w — pubmed.ncbi.nlm.nih.gov
ICH“Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process” Step 4, November 18, 2004 (PDF) — database.ich.org
ICHFinal Concept Paper M18: Framework for Determining the Utility of Comparative Efficacy Studies in Biosimilar Development Programs database.ich.org
Sch l「Acceptable changes in quality attributes of glycosylated biopharmaceuticals」Nature Biotechnology 29(4), 310–312 (2011). doi:10.1038/nbt.1839 — nature.com
Vidarsson, G., Dekkers, G., Rispens, T.「IgG subclasses and allotypes: from structure to effector functions」Frontiers in Immunology 5, 520 (2014). doi:10.3389/fimmu.2014.00520 — pmc.ncbi.nlm.nih.gov
FDA「"Deemed to be a License" Provision of the BPCI Act」 — fda.gov
ICHQ6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products database.ich.org

14. Response Table of Claim and Sources (Audit)

Content	Home
Definition of biosimilars (regardless of the slight difference of clinically inert components, there is no clinically meaningful difference in safety, purity and potency). Compatibility definition (can be replaced without the intervention of predetermined health care workers) and requirements (can be expected by any patient, the risk of alternating or with multiple dose products is not greater). The same mechanism of action has been changed in the revision of "animal testing" in 2022 with the data required for application (an test, toxicity assessment, immunogenicity and clinical trials including PK/PD). 4 years after the first approval of the predecessor, 12 years after the approval	42 U.S.C. 262[Reference 1]https://www.law.cornell.edu/uscode/text/42/262	Facts
CAA is generally more sensitive than CES. Three conditions to consider simplified methods (e.g. clone cell stock, highly purified, sufficient characterization analysis, understanding of quality characteristics and clinical efficacy and evaluation in CAE, and the possibility and clinical meaning of human PK similarity testing). that the sufficientness of data is evaluated in the general body of evidence. October 2025 Compatibility dance (June 2024)	FDA dance (October 2025)[Reference 2]https://www.fda.gov/media/189366/download	Facts
[On March 9, 2026, the FDA approved 82 biosimilars in response to a new guidance on simplifying clinical PK trials, explaining that the dance proposal in October 2025 will reduce the unwanted comparability test that takes 1-3 years.	FDA Press Release (March 9, 2026)[Reference 3]https://www.fda.gov/news-events/press-announcements/fda-takes-further-steps-streamline-biosimilar-development-and-make-medicines-more-affordable	Facts
On June 20, 2024, the amendment of the compatibility guidance was announced, and the idea that the ung test is generally no longer necessary. Nine of the thirteen compatible biosimilars were approved without additional clinical ung test data, and the safety and efficacy with or without compatibility approval.	FDA (June 20, 2024)[Reference 4]https://www.fda.gov/drugs/drug-alerts-and-statements/fda-updates-guidance-interchangeability	Facts
The general name of the biological formulation is the combination of the core name and the suffix of the lowercase four-character without meaning (January 2017)	FDA named[Reference 5]https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonproprietary-naming-biological-products-guidance-industry	Facts
The BLA of Zarxio (filgrastim-sndz) was approved on March 6, 2015.	FDA Approval Statement BLA 125553[Reference Material 6]https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/125553Orig1s000ltr.pdf	Facts
The BLA for Semglee (insulin analog) was accepted and approved on July 29, 2020 under 351(k), and the first biological formulation that 10 mL vials and 3 mL pens were judged to be compatible with any terms of use. The signature date is July 28, 2021.	FDA Approval Statement BLA 761201[Reference Material 7]https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/761201Orig1s000ltr.pdf	Facts
The first biosimilar Zarxio took 24 years from the approval of the predecessor Neupogen to the patient	FDA fact sheet[Reference 8]https://www.fda.gov/media/189382/download	Facts
Explanation of biosimilars by the EU (highly similar in structure, bioactivity, efficacy, safety, and immunogenic profiles). The EU approved the first biosimilars in 2006, not generics (natural roses and complex manufacturing do not allow accurate replication of small unevenness of s). Eighty-six items were approved from 2006 to 2022, and can be applied for at least eight years from prior approval. A reflection paper on the clinical approaches was adopted.	EMA「Biosimilar medicines: Overview」[Reference 9]https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview	Facts
Pharmacies and HMA are compatible with EU-approved biosimilars, including interchanging with the predecessor and substituting with another biosimilar of the same predecessor, and automated replacement in the pharmacy.	/HMA Joint Statement /6 19/2022[Reference Materials 10]https://www.ema.europa.eu/en/documents/public-statement/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf	Facts
Definition of equivalent/homogeneous as bio-co-eds products. It is difficult to demonstrate the essential unevenness, identity, and the similar approach to chemical drugs cannot be applied. Applicants must be eligible for the expiration of the preliminary re-examination period. Evaluation of original method development and management strategy, the importance of predecessor lot analysis results, and method change according to ICH Q5E. Description of the host cell, sugar chain, preparation, and contrast medicine. Quality-comparing tests (construction, physical and chemical properties, primary structural differences are not considered bio-co-edsity, biological properties, impurities, and coagulations are evaluated by multiple methods of the principle, HCP ELISA specificity issues, and quality characteristics related to immunity). Comparison of products manufactured by commercial products and multiple lots.	Ministry of Health, Labour and Welfare Guidelines (February 4, 2020)[Reference Materials 11]https://www.mhlw.go.jp/web/t_doc?dataId=00tc4737&dataType=1&pageNo=1	Facts
In the list of biosimilars approved in Japan, Somatropin BS "Sand" (June 2014) is first published and the name of the sales is "BS" and the name of the shop. Note that this document is based on the personal opinion of the presenter	PMDA (January 28, 2026)[Reference Material 12]https://www.pmda.go.jp/files/000274803.pdf	Facts
The first antibody biosimilar in 2014 in Japan, 18 items were approved by December 2023, that all items were conducted by CES, 64% of the differences in quality characteristics were explained in the results of CES.	Goto et al (2025) abstract[Reference 13]https://pubmed.ncbi.nlm.nih.gov/40971119/	Facts
Q5E is intended to be the same manufacturer (including trusted manufacturers) before and after modification of the manufacturing process, that the equivalent demonstration is not necessarily the same as the quality characteristics, and Step 4 is November 18, 2004.	ICH Q5E[Reference 14]https://database.ich.org/sites/default/files/Q5E%20Guideline.pdf	Facts
The concept paper of ICH M18 was approved on November 19, 2025 and the sensitivity of CES to identify products that are different from quality characteristics is lacking, and the sensitivity of modern analytical technology is background.	ICH M18 Concept Paper[Reference Materials 15]https://database.ich.org/sites/default/files/ICH_M18_Final_Concept_Paper_MCEndorsed_2025_1119.pdf	Facts
Aranesp, R xan/Mabthera and Enbrel's quality profiles obtained from the market from 2007 to 2010 were analyzed and compared the b before and after the manufacturing process changes, showing examples of acceptable variations of products that were sold without changing the display	Sch l et al (2011)[Reference 16]https://www.nature.com/articles/nbt.1839	Facts
N-bonded sugar chain is attached to the 297th position of each IgG heavy chain, and there is a shape such as fucos galactose sialic acid.	Vidarsson et al )[Reference Materials 17]https://pmc.ncbi.nlm.nih.gov/articles/PMC4202688/	Facts
[On March 23, 2020, approval of products including insulin has been delayed to be approved for biological preparations]	FDA "Unauthorized" clause[Reference Materials 18]https://www.fda.gov/drugs/guidance-compliance-regulatory-information/deemed-be-license-provision-bpci-act	Facts
Proteins have biological structural unevenness due to bio processes, and the object is a mixture of post-translation modifiers	ICH Q6B[Reference Materials 19]https://database.ich.org/sites/default/files/Q6B%20Guideline.pdf	Facts
Sugar chain modification when the type of sugar chain is assumed to be 5 or 10 types (15 or 55). Conversion to 24 poles in USA 4-12, European 8 years, Zarxio. Goto et al. stated that about 30% (100-64-6). About 69% of compatible biosimilars (9÷13)	Calculation in this article. The number of types of sugar chains is not the actual type and the ratio of existence in the assumption for explanation. It is not comparable to each other by numbers of different targets and timings. Neither indicates the superiority of the product	The calculation of this paper
Dance on the FDA's comparative validity test, guidance on compatibility, and the final and application period of ICH M18. Scheduled to introduce a designated system for compatibility in Japan	In both cases, at the time of the investigation of this article (September 2026), the primary information that indicates finalization was not confirmed (in this article).	Undetermined / Future
Total number of biosimilars approved in Japan, handling of bio names, policy targets for promoting use, drug price, and penetration rate	The official ag ation of regulators could not be confirmed within the scope of the investigation, or not listed outside the technical commentary.
ing work to create the same distribution rather than the same distribution. The predecessor was "moving distribution", and it was used to determine the standard window from the distribution of commercial lot. catalysis of host cells and the composition distribution of sugar chains into copolymers. Read that the freedom of preparation can be the entrance to the material supplier. Read that the system migration of insulin opens the path of biosimilar compatibility. The performance of the analysis method determines the development period, and the idea of the direct exchange method is required, and the specificity of the analysis reagent depends on the origin of the material. The active ingredient is "similar", the formulation is "better" a symmetrical arrangement	and commentary of this article based on the publication content. It is not the opinion that authors of regulators and papers have been affected
The safety and quality of each product, and the inferiority of the product.	This article explains the mechanism of quality evaluation, manufacturing, and regulation. It is not recommended to evaluate, compare, and switch the efficacy and safety.
Figure 1 - Figure 5 is a drawing for explanation, not the actual data device. Hero image and figure 6 must be an AI generation image	Notes by this article

[Last updated: September 26, 2026 / Sources are limited to primary information (U.S. Law, FDA Notices, Publication Materials, Ministry of Health, Labour and Welfare Guidelines, PMDA Materials, ICH Guidelines, and Review Papers). Because of quality design and analytical reading, they are distinguished from the facts as "explanation".] [Translation 1] Compatibility testing and FDA compatibility are stages of drafting and reviewing, and the final content has not been confirmed. The total number of biosimilars in Japan, policy targets, and spread rates for promoting use are not listed. This article is a technical and regulatory commentary.It does not evaluate and compare the effectiveness and safety of the treatment, and is not recommended for medical advice or to switch the medicine. [Translation 2] All diagrams are illustrations for explanation. Fig. 1 to Fig. 5 is a vector drawing, and Fig. 6 is an AI-generated image.We do not show actual measurement data, equipment and products.